The $50 billion sector is under the spotlight after a number of recent scandals linked to smaller, privately-held Indian ...
The company's specialty business is likely to post double-digit growth YoY in the quarter, despite some sequential moderation ...
Sun Pharmaceutical Industries Ltd , India's largest drugmaker by revenue, on Friday reported a 29.6% rise in fourth-quarter ...
The agency placed the factory under an import alert, meaning US-destined products may be detained ... the most in four months ...
Sun Pharma is expected to benefit from the steady growth in its global specialty and domestic revenue, partially offset by Halol plant being under import alert ... with no FDA-approved treatments).
The NSE Nifty rose 35.75 points, or 0.20 per cent, to 18,321.15. Sun Pharma has been trading in a potential falling wedge pattern on the daily chart. The interim correction has been arrested at ...
Sun Pharma's total revenue from operations rose to Rs 10,931 crore for the March quarter as compared with Rs 9,447 crore in the year-ago period As per the US Food and Drug Administration's ...
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...
Dilip Shanghvi, Sun Pharma’s Managing Director ... The drugmaker said its Halol plant faces an import alert from the US regulatory authorities. The Sun chief, however, told analysts that ...
The company said it was impacted by the U.S. Food and Drug Administration's import alert in December at a ... drugs sales rose 28%. Shares of Sun Pharma settled 2.6% higher after the results ...
